Nevro Corp (NVRO) Given Consensus Rating of “Hold” by Brokerages

Shares of Nevro Corp (NYSE:NVRO) have been assigned a consensus rating of “Hold” from the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $99.71.

A number of analysts recently commented on the stock. Zacks Investment Research raised shares of Nevro from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. Canaccord Genuity decreased their price objective on shares of Nevro from $120.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. BidaskClub downgraded shares of Nevro from a “hold” rating to a “sell” rating in a report on Saturday, October 28th. Northland Securities reissued a “buy” rating and set a $96.00 price objective on shares of Nevro in a report on Tuesday, November 7th. Finally, Leerink Swann reissued an “outperform” rating and set a $110.00 price objective (up previously from $105.00) on shares of Nevro in a report on Tuesday, November 7th.

Shares of Nevro (NVRO) opened at $75.56 on Tuesday. The company has a market cap of $2,232.19, a PE ratio of -52.11 and a beta of -0.59. Nevro has a fifty-two week low of $65.00 and a fifty-two week high of $99.63. The company has a current ratio of 8.78, a quick ratio of 6.81 and a debt-to-equity ratio of 0.59.

Institutional investors and hedge funds have recently made changes to their positions in the business. Hershey Trust Co. acquired a new position in Nevro during the fourth quarter worth about $119,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Nevro during the third quarter worth about $211,000. Public Employees Retirement Association of Colorado acquired a new position in Nevro during the fourth quarter worth about $160,000. Ameritas Investment Partners Inc. raised its position in Nevro by 17.3% during the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after acquiring an additional 358 shares during the last quarter. Finally, PNC Financial Services Group Inc. acquired a new position in Nevro during the second quarter worth about $190,000.

TRADEMARK VIOLATION NOTICE: “Nevro Corp (NVRO) Given Consensus Rating of “Hold” by Brokerages” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/13/nevro-corp-nvro-given-consensus-rating-of-hold-by-brokerages.html.

About Nevro

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Analyst Recommendations for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply